A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

This study is testing whether continuing cancer-fighting systemic therapy after targeted radiation (stereotactic body radiation therapy, or SBRT) can help control kidney cancer that has spread to a small number of sites in the body (called oligometastatic renal cell carcinoma). **You may be eligible if:** - You are 18 or older - You have confirmed kidney cancer (clear cell type) that has spread to 5 or fewer sites - You are in good general health (able to walk and care for yourself) - You have not had recent immunotherapy (or stopped it at least 24 weeks ago) **You may NOT be eligible if:** - You have widespread metastatic disease (such as spread throughout the lining of the brain or belly) - You have HIV, a history of organ transplant, or are on significant immune-suppressing medications - You had a severe immune reaction to a checkpoint inhibitor drug in the past - You are pregnant or breastfeeding - You received a live vaccine within 30 days Talk to your doctor to see if this trial is right for you.